Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 14 Dec 2021
Access Consortium statement on COVID-19 medicines
14 December 2021 - Vaccines have played a critical role in fighting the COVID-19 pandemic. However, medicines can still play ...
Posted by Michael Wonder on 14 Dec 2021
Australia launches National Preventive Health Strategy
13 December 2021 - The Australian Government has today launched the National Preventive Health Strategy, a 10 year plan to improve ...
Posted by Michael Wonder on 14 Dec 2021
New hope offered to rare disease patients
14 December 2021 - Early this month, the world's first therapy to treat spinal muscular atrophy, a rare genetic disorder ...
Posted by Michael Wonder on 14 Dec 2021
Galderma receives FDA approval for new Sculptra label, offering more options to aesthetic partners
13 December 2021 - New label update allows for immediate use after reconstitution and more convenient administration of Sculptra with the ...
Posted by Michael Wonder on 14 Dec 2021
mRNA manufacturing facility will deliver long term health benefits for Australians
14 December 2021 - Medicines Australia welcomes the announcement that Australia will manufacture mRNA vaccines in a deal struck with ...
Posted by Michael Wonder on 13 Dec 2021
EMA publishes agenda for 13-16 CHMP meeting
13 December 2021 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 13 Dec 2021
Veru announces FDA approval of Entadfi, a new treatment for benign prostatic hyperplasia
13 December 2021 - Commercialisation will start early calendar year 2022. ...
Posted by Michael Wonder on 13 Dec 2021
Pfizer/BioNTech vaccine approved for children by Swiss regulator
10 December 2021 - The Swiss medical regulator has approved the use of Pfizer/BioNTech’s Covid-19 vaccine for children aged five to ...
Posted by Michael Wonder on 13 Dec 2021
InterVene’s BlueLeaf Endovenous Valve Formation System granted breakthrough device designation by the FDA
13 December 2021 - InterVene announced today that it has received breakthrough device designation by the FDA for the company’s BlueLeaf ...
Posted by Michael Wonder on 13 Dec 2021
SMC - December 2021 decisions
13 December 2021 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has published ...
Posted by Michael Wonder on 13 Dec 2021
Moderna vaccine deal to produce 100 million doses in Melbourne reached by Federal and Victorian Governments
13 December 2021 - Australia is poised to become the largest producer of mRNA vaccines outside the US and Europe ...
Posted by Michael Wonder on 13 Dec 2021
Forecast 2 for the 2021 rebate from side agreements
13 December 2021 - In a new report to the government, TLV forecasts that the pharmaceutical companies will pay approximately ...
Posted by Michael Wonder on 13 Dec 2021
European Commission approves Pfizer's Cibinqo (abrocitinib) for the treatment of adults with moderate to severe atopic dermatitis
10 December 2021 - Cibinqo is a once daily oral treatment with proven efficacy demonstrated in a large scale clinical ...
Posted by Michael Wonder on 13 Dec 2021
International regulators recommend use of remote inspections as complementary tool beyond pandemic
13 December 2021 - Remote inspections have been useful in maintaining regulatory oversight during the COVID-19 pandemic, but cannot fully replace ...
Posted by Michael Wonder on 13 Dec 2021
ACCC helps to protect Australians against medicine shortages caused by COVID-19
10 December 2021 - Medicine shortages from the COVID-19 pandemic will continue to be actively managed by Medicines Australia and ...